Detalhe da pesquisa
1.
A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.
J Neurooncol;
155(3): 297-306, 2021 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34689306
2.
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
Cancer;
126(12): 2821-2828, 2020 06 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32154928
3.
Primary Central Nervous System Lymphoma-PART 2: Modern Therapeutic Management and Future Directions.
Oncology (Williston Park);
32(2): e11-e19, 2018 02 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29492949
4.
Primary Central Nervous System Lymphoma-PART 1: Epidemiology, Diagnosis, Staging, and Prognosis.
Oncology (Williston Park);
32(1): 17-22, 2018 01 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29447417
5.
A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.
J Neurooncol;
129(1): 139-46, 2016 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27300524
6.
Central Nervous System Cancers, Version 1.2015.
J Natl Compr Canc Netw;
13(10): 1191-202, 2015 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26483059
7.
Managing Disease and Therapy-Related Complications in Patients with Central Nervous System Tumors.
Curr Treat Options Oncol;
16(8): 38, 2015 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26143268
8.
Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines.
J Natl Compr Canc Netw;
12(11): 1517-23, 2014 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25361798
9.
Diffusion abnormalities of the corpus callosum in patients receiving bevacizumab for malignant brain tumors: suspected treatment toxicity.
J Neurooncol;
118(1): 147-53, 2014 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24574050
10.
A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.
J Neurooncol;
117(1): 93-101, 2014 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24449400
11.
Development of a symptom index for patients with primary brain tumors.
Value Health;
17(1): 62-9, 2014.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24438718
12.
Central nervous system cancers.
J Natl Compr Canc Netw;
11(9): 1114-51, 2013 Sep 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24029126
13.
Widespread disseminated osseous metastases of intracranial meningioma with over 27-year-survivorship: a unique, idiosyncratic case.
J Neurooncol;
139(3): 781-783, 2018 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29948769
14.
Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases.
J Neurooncol;
112(2): 247-55, 2013 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23354655
15.
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
J Clin Oncol;
41(6): 1285-1295, 2023 02 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36260832
16.
A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.
Neuro Oncol;
25(3): 557-565, 2023 03 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35948282
17.
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Clin Cancer Res;
29(19): 3882-3891, 2023 10 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37490286
18.
Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma.
Cancer;
118(15): 3743-8, 2012 Aug 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22179954
19.
Metastatic glioblastoma: case presentations and a review of the literature.
J Neurooncol;
107(1): 21-7, 2012 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21964740
20.
Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
J Neurooncol;
110(2): 237-43, 2012 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22875709